natgillin/translations-raw huggingface dataset:
at reducere forhøjede kalciumniveauer i blodet (hyperkalcæmi) hos patienter med cancer i biskjoldbruskkirtlerne, at reducere forhøjede kalciumniveauer i blodet (hyperkalcæmi) hos patienter med primær hyperparathyreoidisme, der fortsat har forhøjede kalciumniveauer efter, de har fået fjernet biskjoldbruskkirtlerne eller hos hvem, det ikke er muligt at fjerne biskjoldbruskkirtlerne.
to reduce high levels of calcium in the blood (hypercalcaemia) in patients with parathyroid cancer to reduce high levels of calcium in the blood (hypercalcaemia) in patients with primary hyperparathyroidism who still have high calcium levels after removal of the parathyroid gland or when removal of the gland is not possible.
At returnere ubrugte kapsler ved behandlingens afslutning (bortskaffelse vil afhænge af lokale retningslinjer)
To return unused capsules at the end of the treatment (disposal will depend on local requirements)
At Revlimid kan forårsage neutropeni og trombocytopeni og at regelmæssige blodtest er nødvendige
That Revlimid may cause neutropenia and thrombocytopenia and the need for regular blood tests
At Revlimid kan forårsage venøs og arteriel tromboemboli
That Revlimid may cause venous and arterial thromboembolism
At risikoen for infusionsreaktioner er højest i behandlingens første uge
That the risk of infusion reactions is highest in first week of therapy
At risikoen for PML øges ved forlænget behandlingsvarighed, og at behandling ud over 24 måneder medfører en yderligere risiko og andre faktorer associeret med en øget risiko for at udvikle PML
That the risk of PML increases with increasing duration of treatment and that treatment beyond 24 months carries additional risk and other factors associated with an increased risk for the development of PML
At Ruconest udvindes af mælken fra transgene kaniner og indeholder spor af kaninprotein
That Ruconest is derived from milk of transgenic rabbits and contains trace of rabbit proteins
At samtidig administration af STAYVEER og cyclosporin er kontraindiceret.
That co-administration of STAYVEER with cyclosporine is contraindicated.
At samtidig administration af Tracleer og ciclosporin er kontraindiceret.
That co-administration of Tracleer with cyclosporine is contraindicated.
At sikkerhedsdatabasen for STAYVEER ved indikationen til reduktion af antallet af nye fingersår hos patienter med systemisk sklerose og akut fingersårssygdom er begrænset og at læger opfordres til at inkludere patienter i overvågningsprogrammet/-registeret med henblik på at øge kendskabet til produktet.
That the safety database of STAYVEER in the indication to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease is limited and physicians are encouraged to enrol patients in the surveillance programme/registry to further increase knowledge about the product.
At sikkerhedsdatabasen for Thelin er begrænset, og at læger opfordres til at indskrive patienter i et overvågningsprogram med henblik på at øge kendskabet til forekomsten af væsentlige bivirkninger (ADR’er).
That the safety database of Thelin is limited and physicians are encouraged to enrol patients in a surveillance programme to increase knowledge about the incidence of important adverse drug reactions (ADRs).
At sikkerhedsdatabasen for Tracleer ved indikationen til reduktion af antallet af nye fingersår hos patienter med systemisk sklerose og akut fingersårssygdom er begrænset og at læger opfordres til at inkludere patienter i overvågningsprogrammet/-registeret med henblik på at øge kendskabet til produktet.
That the safety database of Tracleer in the indication to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease is limited and physicians are encouraged to enrol patients in the surveillance programme/registry to further increase knowledge about the product.
At sikre sig ved udskrivning at den rigtige styrke er nævnt på recepten;
When prescribing to make sure that the correct strength is mentioned in the prescription slip;
At sikre sig ved udskrivning, at den korrekte styrke er nævnt på recepten.
When prescribing, to ensure that the correct strength is mentioned on the prescription
At sikre, at kvinder i den fødedygtige alder, ikke er gravide og anvender sikker kontraception, inden behandlingen med Opsumit startes.
To ensure females of childbearing potential are not pregnant and are on reliable contraception prior to starting Opsumit;
At skiftet fra en insulinbehandling til en anden kun skal ske, når det er ordineret af deres læge;
That the switch from one insulin therapy to another should only be done when prescribed by their healthcare provider;
At STAYVEER er hepatotoksisk
That STAYVEER is hepatotoxic
At STAYVEER er teratogent hos dyr
That STAYVEER is teratogenic in animals
At STAYVEER medfører et fald i hæmoglobin og at der er behov for regelmæssige blodprøver
That STAYVEER causes a decrease in haemoglobin and the need for regular blood tests
At stigninger i transaminaser kan forekommer hos patienter, der er blevet behandlet med Exjade
That rises in serum transaminases may occur in patients treated with EXJADE
At Stribild ikke bør påbegyndes hos patienter med kreatininclearance under 70 ml/min.
That Stribild should not be initiated in patients with creatinine clearance below 70 mL/min.
At sygdommen er multicentrisk, vil sige, at den omfatter flere lymfeknuder foruden andre organer i kroppen.
Multicentric means that the disease affects several lymph nodes as well as other organs in the body.
At såfremt behandlingen seponeres i mere end 7 dage, skal MabCampath genindsættes med gradvis dosisoptrapning
That if therapy is withheld for more than 7 days then MabCampath should be reinstituted with gradual dose escalation
At såfremt reaktionen er moderat eller alvorlig, bør dosering fortsætte på samme niveau (dvs. ingen dosisoptrapning), indtil hver dosis tolereres godt.
That if the reaction is moderate or severe dosing should continue at the same level (ie no dose escalation) until each dose is well tolerated
at tacrolimus-koncentrationerne
original dose and tacrolimus level
At tage 3 separate blistere à 1 mg giver mere insulin i lungerne end 1 enkelt blister à 3 mg.
Taking three separate 1 mg blisters delivers more insulin to your lungs than a single 3 mg blister does.
At tage 3 separate blistere à 1 mg giver mere insulin i lungerne end 1 enkelt blister à 3 mg.
Taking three separate 1 mg unit dose blisters delivers more insulin to your lungs than a single 3 mg unit dose blister does.
At tage acetylsalicylsyre før De tager Pelzont vil ikke mindske Deres rødmen mere, end hvis De tager Pelzont alene.
Taking aspirin before you take Pelzont does not reduce your flushing more than taking Pelzont alone.
At tage acetylsalicylsyre før De tager Tredaptive vil ikke mindske Deres rødmen mere, end hvis De tager Tredaptive alene.
Taking aspirin before you take Tredaptive does not reduce your flushing more than taking Tredaptive alone.
At tage acetylsalicylsyre før De tager Trevaclyn vil ikke mindske Deres rødmen mere, end hvis De tager Trevaclyn alene.
Taking aspirin before you take Trevaclyn does not reduce your flushing more than taking Trevaclyn alone.
At Tasigna bliver metaboliseret af CYP3A4, og at potente inhibitorer eller inducere af dette enzym kan påvirke eksponeringen for Tasigna signifikant
That Tasigna is metabolised by CYP3A4 and that strong inhibitors or inducers of this enzyme may significantly affect exposure to Tasigna.
At Tasigna kan forårsage forlænget QT-interval, og at Tasigna skal anvendes med forsigtighed til patienter, som har eller som har signifikant risiko for at udvikle forlænget QTc.
That Tasigna can cause prolongation of the QT interval and that Tasigna should be used with caution in patients who have or who are at significant risk of developing prolongation of QTc.
At Tasigna kan forårsage væskeretention, hjertesvigt og lungeødem.
That Tasigna may cause fluid retention, cardiac failure and pulmonary oedema
At terapeutiske doser af Bronchitol kun må ordineres, hvis patienten har bestået vurderingen af initialdosen.
That therapeutic doses of Bronchitol should only be prescribed if the patient has passed the initiation dose assessment.
At thalidomid kan findes i sæd og nødvendigheden af at anvende kondom, hvis den seksuelle partner er gravid, eller er en kvinde i den fertile alder og ikke anvender sikker kontraception
That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a women with childbearing potential not using effective contraception
At thalidomid kan findes i sæd og nødvendigheden af at anvende kondom, hvis seksualpartneren er gravid eller er en kvinde i den fertile alder, som ikke anvender sikker kontraception
That thalidomide is found in semen and the need to use condoms if sexual partner is pregnant or is a women with childbearing potential not on effective contraception
At Thalidomide Celgene er teratogent
That Thalidomide Celgene is teratogenic
At Thalidomide Celgene ikke må videregives til andre
That Thalidomide Celgene must not be given to any other person
At Thalidomide Celgene kan forårsage venøs og arteriel tromboemboli, kardiovaskulære hændelser samt neuropati
That Thalidomide Celgene may cause venous and arterial thromboembolism, cardiovascular events and neuropathy
At Thelin er hepatotoksisk
That Thelin is hepatotoxic
At Thelin er levertoksisk, og at de er nødt til at møde op til regelmæssig blodprøvetagning.
That Thelin is hepatotoxic and they will need to attend for regular blood tests
At Thelin er teratogent
That Thelin is teratogenic
At Thelin er teratogent, og at kvinder i den fødedygtige alder skal bruge sikker prævention.
That Thelin is teratogenic and that women of child bearing age must use effective contraception
At Thelin er teratogent.
That Thelin is teratogenic
At tiden til tumorprogression var forkortet hos patienter, som har fremskreden hoved- og halscancer, og som får strålebehandling, når disse stoffer blev administreret for at opnå en hæmoglobinkoncentration højere end 14 g/dl (8,7 mmol/l)
hortened time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a haemoglobin of greater than 14 g/dl (8.7 mmol/l),
at tilstanden er potentielt livstruende, at der ikke findes nogen alternativ behandling, kan hydroxocobalamin gives til gravide.
the potentially life threatening condition, the lack of alternative treatment, hydroxocobalamin may be given to a pregnant woman.
At Tracleer er hepatotoksiskt
That Tracleer is hepatotoxic
At Tracleer er teratogent hos dyr
That Tracleer is teratogenic in animals
At Tracleer medfører et fald i hæmoglobin og at der er behov for regelmæssige blodprøver
That Tracleer causes a decrease in haemoglobin and the need for regular blood tests
At Tresiba er tilgængelig i to styrker;
That Tresiba is available in 2 strengths;
At Truvada kun bør anvendes til patienter med nedsat nyrefunktion, hvis det vurderes, at de potentielle fordele opvejer de potentielle risici
That Truvada should only be used in patients with impaired renal function if the potential benefits are considered to outweigh the potential risks
At udføre en række bøje- og strækøvelser med fingeren flere gange om dagen i flere måneder.
Perform a series of finger flexion and extension exercises several times a day for several months.
At udføre et registerstudie uden intervention efter udstedelse af markedsføringstilladelse af patienter behandlet med pomalidomid for relaps og refraktær myelomatose for at overvåge forekomsten af bivirkninger og for at overvåge implementeringen og overholdelsen af Celgenes program til svangerskabsforebyggelse og off label-anvendelse og det kontrollerede distributionssystem på landebasis efter aftale med den relevante nationale myndighed
To conduct a non-interventional post-authorisation registry of patients treated with pomalidomide for relapsed and refractory multiple myeloma to monitor incidence of adverse reactions and to monitor the implementation and compliance of Celgene pregnancy prevention programme and off-label use and controlled distribution system on a country basis in agreement with relevant National Competent Authorities
At udlevere patientkortet til patienterne;
To provide patients with the patient card;
at udløbdatoen ikke er overskredet.
the expiry date has not passed
at udløbsdatoen ikke er overskredet
it has not passed its expiry date
at udløbsdatoen ikke er overskredet
the expiry date has not passed
at udløbsdatoen ikke er overskredet.
it has not passed its expiry date
At undersøge værdien af andre biomarkører end PD-L1-ekspressionsstatus ved tumorcellemembran-niveau ved immunhistokemisk (IHC) analyse (f.eks. andre genom-baserede metoder / analyser og relaterede cut-offs, som kan vise sig at være mere følsomme og specifikke til at forudse respons på behandlingen, baseret på PD-L1, PD-L2, tumorinfiltrerende lymfocytter med måling af CD8+T-densitet, RNA-signatur, ekspression af komponenter fra antigenpræsenterende komplekser og/eller andre hæmmende checkpoint-receptorer/ligander i tumor etc.) som prædiktive for virkningen af nivolumab og/eller nivolumab + ipilimumab- kombinationsterapi.
To further investigate the value of biomarkers other than PD-L1 expression status at tumour cell membrane level by IHC (e.g., other genomic-based methods / assays, and associated cut-offs, that might prove more sensitive and specific in predicting response to treatment based on PD-L1, PD-L2, tumour infiltrating lymphocytes with measurement of CD8+T density, RNA signature, expression of components of antigen-presentation complexes and/or other inhibitory checkpoint receptors/ligands within tumour, etc.) as predictive of nivolumab and/or nivolumab + ipilimumab combination therapy efficacy.
At Vibativ giver risiko for nefrotoksicitet, herunder øget risiko for dødelighed hos patienter med allerede eksisterende akut nyresvigt, og er derfor kontraindiceret hos patienter med allerede eksisterende akut nyresvigt og hos patienter med kreatininclearance < 30 ml/min, herunder patienter i hæmodialysebehandling.
That Vibativ has a risk of nephrotoxicity including increased risk of mortality in patients with pre existing acute renal failure and is therefore contraindicated in patients with pre-existing acute renal failure and in patients with creatinine clearance < 30ml/min, including patients undergoing haemodialysis.
At Viread ikke anbefales til pædiatriske patienter med nedsat nyrefunktion
That Viread is not recommended for use in paediatric patients with renal impairment
At Viread kan forårsage en reduktion i BMD og virkningerne af ændringer i BMD associeret med Viread på knoglesundheden på længere sigt og fremtidig frakturrisiko ikke kendes på nuværende tidspunkt hos pædiatriske patienter
That Viread may cause a reduction in BMD and the effects of Viread associated changes in BMD on long term bone health and future fracture risk are currently unknown in paediatric patients
At Viread kun bør bruges til patienter med nedsat nyrefunktion, hvis de potentielle fordele ved behandlingen anses for at veje tungere end de potentielle risici
That Viread should only be used in patients with impaired renal function if the potential benefits of treatment are considered to outweigh the potential risks
At visse bivirkninger i forbindelse med indberetning skal opprioriteres, dvs. dødelige og livstruende bivirkninger, uventede alvorlige bivirkninger, bivirkninger af speciel interesse (AESI).
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
At visse bivirkninger i forbindelse med indberetning skal opprioriteres, dvs. fatale og livstruende bivirkninger, uventede alvorlige bivirkninger, bivirkninger af speciel interese (AESI).
Adverse events to be prioritised for reporting, i.e. fatal and life-threatening adverse reactions, unexpected severe adverse reactions, adverse events of special interest (AESI).
At Volibris ikke må anvendes, hvis en kvinde er gravid eller har mulighed for at blive gravid.
That Volibris cannot be taken if a woman is or might become pregnant.
At Volibris ikke må påbegyndes, hvis patienten er gravid.
That Volibris cannot be initiated if patient is pregnant.
At Volibris kan forårsage alvorlige skader hos fostre, der er undfanget før, under eller inden for en måned efter ophør med behandlingen.
That Volibris may cause serious birth defects in unborn babies conceived before, during, or within a month after stopping treatment.
At Volibris kan forårsage leverskader.
That Volibris may cause liver injury.
At Volibris muligvis er levertoksisk
That Volibris is potentially hepatotoxic
At Volibrisbehandling skal indledes med forsigtighed hos patienter med svært nedsat nyrefunktion.
That Volibris should be initiated with caution in patients with severe renal impairment.
At vurdere forekomst og udfald af graviditet hos kvinder i den fødedygtige alder, som er behandlet med lomitapid og beslutter at fortsætte graviditeten efter rådgivning fra læge med erfaring i teratologi
To evaluate the occurrence and outcomes of pregnancy in females of reproductive potential treated with lomitapide who decide to continue the pregnancy following advice from a teratologist.
At vurdere lomitapids langsigtede virkning til opretholdelse af kontrollen med serumlipidniveauet i klinisk praksis
To evaluate the long-term effectiveness of lomitapide in maintaining control of serum lipid levels in clinical practice.
At vurdere, om de læger, der ordinerer lomitapid, følger anbefalingerne for screening og overvågning i produktinformationen og uddannelsesmaterialet
To evaluate whether prescribers of lomitapide are following the screening and monitoring recommendations as specified in the product information and the educational materials.
at være klinisk signifikante.
clinically significant.
at ændres ved samtidig
change upon co-administration
at øge dosis for både
increase in the dose of both
at øge virkningen af nogle lægemidler, der bruges til behandling af HIV-infektioner
to increase levels of some medicines used to treat HIV infection
At øget eksponering kan forekomme i visse befolkningsgrupper og øge risikoen for vedvarende intolerabilitet:
That increased exposure might occur in certain populations and increase the risk of persistent intolerability:
At, hvis en kvinde i den fertile alder har brug for at ændre eller stoppe brugen af prævention, skal hun informere lægen, som ordinerer hendes prævention, om, at hun tager Volibris.
That if a woman of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing her contraception that she is taking Volibris.
At, hvis en kvinde i den fertile alder har brug for at ændre eller stoppe brugen af prævention, skal hun informere lægen, som ordinerer hendes prævention, om, at hun tager Volibris.
That if a women of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing her contraception that she is taking Volibris.
At, hvis en kvinde i den fertile alder har brug for at ændre eller stoppe brugen af prævention, skal hun informere lægen, som ordinerer Volibris.
That if a women of child-bearing potential needs to change or stop her method of contraception she should inform the physician prescribing Volibris.
Ataksi
Ataxia
Ataksi
Uncommon
Ataksi Svimmelhed
Anhidrosis
Ataksi Svimmelhed
Ataxia Dizziness
Ataksi Svimmelhed
Cholecystitis Cholelithiasis
Ataksi, balanceforstyrrelser
Deafness (Including Hypoacusis), Tinnitus
ataksi, opmærksomhedsforstyrrelse, hepatisk encefalopati, bevidsthedstab, talebesvær, forbigående iskæmisk
ataxia, disturbance in attention, hepatic encephalopathy, loss of consciousness, speech disorder, transient ischaemic attack, posterior reversible encephalopathy syndrome
ataksi, opmærksomhedsforstyrrelse, hepatisk encefalopati, bevidsthedstab, talebesvær, forbigående iskæmisk anfald, posterior reversibelt encefalopatisyndrom
ataxia, disturbance in attention, hepatic encephalopathy, loss of consciousness, speech disorder, transient ischaemic attack, posterior reversible encephalopathy syndrome
ataksi, smags- forandringer
Ataxia, taste alteration
Ataluren forventes ligeledes ikke at være en in vivo inducer af cytokrom P450 isoenzymer.
Similarly, ataluren is not expected in vivo to be an inducer of cytochrome P450 isoenzymes.
Ataluren metaboliseres ved konjugation i lever og tarme via uridin diphosphat glucuronosyltransferase (UGT) -enzymer, hovedsagligt UGT1A9.
Ataluren is metabolized by conjugation via uridine diphosphate glucuronosyltransferase (UGT) enzymes, predominantly UGT1A9 in liver and intestine.
Ataluren må ikke administreres samtidig med intravenøse aminoglykosider baseret på tilfælde af nedsat nyrefunktion observeret i et klinisk forsøg hos patienter med nmCF (nonsense mutation Cystisk Fibrose) (se pkt.
Ataluren should not be co-administered with intravenous aminoglycosides, based on cases of decreased renal function observed in a clinical trial in patients with nmCF (see section 4.3 ).
Ataxi
Ataxia
Atazanavir (300 mg én gang
Atazanavir (300 mg once daily)
Atazanavir (aften): alle administreret
Atazanavir (pm): all administered with food
Atazanavir + cobicistat + emtricitabin og tenofovirdisoproxilfumarat i fastdosis-kombination var non-inferiore med hensyn til at opnå hiv-1-rna < 50 kopier/ml, sammenlignet med atazanavir
Atazanavir + cobicistat + emtricitabine and tenofovir disoproxil fumarate fixed-dose combination was non-inferior in achieving HIV-1 RNA < 50 copies/ml when compared to atazanavir + ritonavir
Atazanavir + ritonavir/ dolutegravir
Atazanavir+ ritonavir/ Dolutegravir
atazanavir /ritonavir /raltegravir (raltegravir 400 mg to gange dagligt)
atazanavir /ritonavir /raltegravir (raltegravir 400 mg Twice Daily)
atazanavir 300 mg med ritonavir
atazanavir is 300 mg with
Atazanavir 300 mg med ritonavir 100 mg
atazanavir 300 mg with ritonavir 100 mg
Atazanavir 300 mg og ritonavir 100
300 mg and ritonavir 100 mg (n=33)
atazanavir 300 mg og ritonavir 100 mg én gang dagligt
atazanavir 300 mg and ritonavir 100 mg once daily
Atazanavir 300 mg x 1
300 mg once daily
Atazanavir 300 mg én gang dagligt
Atazanavir 300 mg once daily
atazanavir 300 mg/ritonavir 100
300 mg/ritonavir 100 mg once
atazanavir 300 mg/ritonavir 100
Atazanavir (pm):
Atazanavir 300 mg/ritonavir 100 mg en gang dagligt (daclatasvir 20 mg en gang dagligt)
Atazanavir 300 mg/ritonavir 100 mg once daily (daclatasvir 20 mg once daily)
Atazanavir 400 mg 1 gang daglig (maraviroc 300 mg 2 gange daglig)
(maraviroc 300 mg BID)
atazanavir alene.
compared to atazanavir alone.
Atazanavir AUC ↑18% (↑6,5%
Atazanavir AUC ↑18% (↑6.5
atazanavir AUC ↓ 35 %
atazanavir AUC ↓ 35
Atazanavir AUC ↔6% (↓10%
Atazanavir AUC ↔6% (↓10% ↑26%)
Atazanavir AUC 2,3% (↓13%
Atazanavir AUC 2.3% (↓13
Atazanavir boostet med
Atazanavir boosted with
Atazanavir boostet med ritonavir (300 mg/ 100 mg én gang dagligt)/ ledipasvir (90 mg én gang dagligt)c/ sofosbuvir (400 mg én gang dagligt)c,d
Atazanavir boosted with ritonavir (300 mg/ 100 mg once daily)/ ledipasvir (90 mg once daily)c/ sofosbuvir (400 mg once daily)c, d
Atazanavir boostet med ritonavir (300/100 mg én gang dagligt) + emtricitabin/ tenofovirdisoproxilfumarat (200/300 mg én gang dagligt)/sofosbuvir/ velpatasvir (400/100 mg én gang dagligt)c, d
Atazanavir boosted with ritonavir (300/ 100 mg once daily) + emtricitabine/ tenofovir disoproxil fumarate (200 / 300 mg once daily)/ sofosbuvir/ velpatasvir (400/ 100 mg once daily)c, d
atazanavir bør dosis af Vitekta
atazanavir, the dose of Vitekta
atazanavir Cmaks. ↓ 25 %
atazanavir Cmax ↓ 25
atazanavir Cmin ↓ 49 %
atazanavir Cmin ↓ 49
Atazanavir Cmin ↔12% (↓16%
Atazanavir Cmin ↔12% (↓16% ↑49%)
atazanavir Cmin  52 % atazanavir Cmax  11 %
atazanavir Cmin ↑ 52
atazanavir er 300 mg,
atazanavir is 300 mg,
atazanavir er 300 mg, uden
atazanavir is 300 mg,
Atazanavir er en CYP3A4- og UGT1A1-hæmmer.
Atazanavir is an inhibitor of CYP3A4 and UGT1A1.